Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the diagnostic efficacy of <sup>18</sup> F-FDG PET/CT in distinguishing between pulmonary tuberculosis (PTB) and lung cancer in solitary pulmonary nodule (SPN) in a country with a high prevalence of PTB.
|
31837121 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
|
30218317 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that FDG-PET evaluation in metastatic bone lesions could be useful to predict initial pain and subsequent clinical outcomes of local bone status in initially diagnosed lung cancer patients with bone metastasis.
|
30883012 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirty-three patients with lung cancer and ILD who underwent <sup>18</sup>F-FDG PET/CT and were treated with chemotherapy at Kumamoto University Hospital between April 2006 and March 2018 were retrospectively analyzed.
|
31781994 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To analyze the predictive value of cardiovascular events from inflammation and arterial calcification in patients who underwent an 18F-FDG PET/CT for lung cancer.
|
30715503 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the diagnostic capacity of dynamic fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) and dual-time-point (DTP) PET/CT to explore the optimal scan timing for nodal staging in lung cancer.
|
30911883 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ten patients with lung cancer who underwent two baseline whole-body [<sup>18</sup>F]FDG PET/low-dose (LD) CT scans within 1 week were included.
|
29789994 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To map functional bone marrow (BM) by 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients prior to, during, and after treatment.
|
29916117 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
|
30535744 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore the relationships between 18F-FDG PET/CT derived parameters such as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG) of primary tumor and clinical stage in different histopathologic subtypes of lung cancer.
|
30916535 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to assess the effects of a ketogenic diet (as an alternative protocol to fasting) on tumor glucose metabolism assessed by [<sup>18</sup>F]FDG positron emission tomography (PET) in a mouse model of lung cancer.
|
29968182 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty-four patients with non-resectable lung cancer underwent [<sup>18</sup>F]FDG and [<sup>18</sup>F]FMISO PET/CT before (pre-RT) and during radiotherapy (around 42 Gy, per-RT).
|
31432388 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD.
|
30348701 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many benign pulmonary lesions, especially sarcoidosis, are metabolically active and are indistinguishable from lung cancer using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging.
|
31367534 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT.
|
30365151 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, the role of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG PET) has expanded in the last decades from a stand-alone diagnostic tool to a versatile instrument integrated with computed tomography (CT), with a prominent role in lung cancer radiotherapy.
|
30206495 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positron emission tomography with 2‑deoxy-2-[fluorine-18] fluoro-d-glucose integrated with computed tomography (18F-FDG-PET/CT) has an established role in the initial diagnosis and staging of lung cancer.
|
29116336 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 52-year-old man presented a mixed low-density lesion with high FDG uptake in hepatic segment VIII after gamma knife therapy for lung cancer, which was easily misdiagnosed as hepatic metastasis.
|
30222682 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In prostate and breast cancer, WB-MRI-DWI is useful in assessing the response of bone lesions to therapy and to detecting early non-responders, while in lung cancer the method shows a similar sensitivity to 18F-FDG PET/CT in the detection of bone metastases.
|
29987207 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
By utilizing <sup>18</sup>F-FDG PET/CT, researchers are able to measure dynamic changes in the glucose metabolism in genetically engineered mouse models (GEMMs) of lung cancer following a therapeutic intervention with targeted therapies.
|
30080208 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some quantitative parameters, such as the use of 18F-FDG PET/CT-derived standard uptake values (SUV), have already been incorporated into current practice as it provides important information for diagnosis, staging, and treatment response of patients with lung cancer.
|
30302536 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adrenal Hemangioma Definite Diagnosis on CT, MRI, and FDG PET in a Patient With Primary Lung Cancer.
|
29561525 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
|
30352608 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of 18-FDG PET/CT had been well established in other more prevalent malignancies such as colorectal and lung cancer; however, this is not as well defined in cholangiocarcinoma.
|
28905105 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thyroid gland characteristics of patients with a clinical diagnosis of NF1 who underwent <sup>18</sup>F-FDG PET/CT imaging for the first time to distinguish benign neurofibroma from malignant peripheral nerve sheath tumor (MPNST) at our institution (<i>n</i> = 69) were compared to PET/CT imaging of sarcoidosis (<i>n</i> = 25) and early stage lung cancer (T<sub>1</sub>N<sub>0</sub>M<sub>0</sub> tumors, <i>n</i> = 15) patients.
|
30023349 |
2018 |